View printer-friendly version

Brisbane, Australia, 6 June 2019 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce the publication of results from the Breathe Easy paediatric clinical study in the open access journal Respiratory Research. The paper, entitled “A prospective multicentre study testing the diagnostic accuracy of an automated cough sound centred analytic system for the identification of common respiratory disorders in children” reports the detailed peer-reviewed results from the study.

The prospective, multi-centre Breathe Easy paediatric study recruited 585 children at Joondalup Health Campus and Princess Margaret Hospital in Perth, Western Australia. The study demonstrated that ResApp’s smartphone app had high accuracy (between 81% and 97%) in diagnosing asthma, croup, pneumonia, lower respiratory tract disease and bronchiolitis when compared to a diagnosis reached by a panel of paediatricians after they had reviewed hospital charts and conducted all available clinical investigations.

Tony Keating, CEO and Managing Director of ResApp commented, “The publication of the Breathe Easy study in a high impact, peer-reviewed journal is an important milestone in the validation of our technology. We would like to congratulate the teams at Joondalup Health Campus, Princess Margaret Hospital, Curtin University and The University of Queensland on this achievement.”

The publication can be found here.

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies at leading hospitals in the United States and Australia have demonstrated accurate diagnosis of pneumonia, asthma/reactive airway disease, bronchiolitis, croup, chronic obstructive pulmonary disease and upper respiratory tract infections. ResApp has also obtained excellent results for screening of obstructive sleep apnoea in a double-blind, prospective clinical study. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world. For more information, please visit www.resapphealth.com.au

Contacts
Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Brian Leedman
VP, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000

CONTACT US
+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations

    

LEGAL
Terms of Use
Privacy Policy

ResAppDx-US is pending review of a request for De Novo classification and is not available for sale in the United States.

© 2019 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.